9 Analysts Have This to Say About Immunovant
Portfolio Pulse from Benzinga Insights
Over the past 3 months, 9 analysts have published their opinion on Immunovant (NASDAQ:IMVT) stock. The average price target for the stock is $26.67, an increase of 1.29% from the previous average price target of $26.33. Out of the 9 analysts, 8 have given a bullish rating while 1 has given a somewhat bearish rating.
July 18, 2023 | 1:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have given a bullish outlook on Immunovant's stock with an average price target of $26.67, indicating potential upside. However, one analyst has a somewhat bearish view.
The majority of analysts have a bullish outlook on Immunovant, which could drive the stock price up in the short term. However, the presence of a somewhat bearish view indicates some level of uncertainty and potential downside risk.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100